Navigation Links
Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
Date:5/9/2008

WALTHAM, Mass., May 9 /PRNewswire-FirstCall/ -- Inverness Medical Innovations (Amex: IMA) today announced that its previously announced acquisition of Matria Healthcare, Inc. was successfully completed and effective prior to the opening of business today, May 9, 2008. Matria, headquartered in Marietta, Georgia, provides comprehensive, integrated health management services particularly in the areas of women's and children's health, cardiology and oncology. The final purchase price consisted of approximately $143.9 million, and approximately 1.8 million shares of Inverness Series B Convertible Perpetual Preferred Stock (Amex: IMA.PR.B). In addition, existing options to purchase Matria stock have been assumed by Inverness and have converted into options to purchase approximately 1.5 million shares of Inverness common stock.

As a result of the merger, Matria's common stock will no longer trade on The NASDAQ Global Select Market. Pursuant to the merger, each outstanding share of Matria common stock, not owned by Matria or its affiliates and not subject to appraisal rights, has been automatically converted into the right to receive (i) $6.50 in cash, without interest, and (ii) a portion of a share of Series B Preferred Stock of Inverness. Inverness expects that the shares of Series B Preferred Stock will begin trading on the American Stock Exchange LLC as of the opening of the market today, May 9, 2008. The listing approval of the American Stock Exchange LLC for the shares of Series B Preferred Stock is contingent upon Inverness being in compliance with all applicable listing standards on the date it begins trading on the Exchange, and may be rescinded if Inverness is not in compliance with such standards.

About Inverness

By
'/>"/>

SOURCE Inverness Medical Innovations
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , , ... By Susan Catalano, Ph.D., Acumen Pharmaceuticals, Sylvia de Bruin, Joe Bosworth, ... Corporation, , 1311 Orleans Drive, Sunnyvale, CA 94089. , ... G-protein coupled receptors (GPCRs are the largest class of pharmaceutical ...
... and Ario de Marco , EMBL Protein Expression ... , Introduction ,Immobilized Metal ion Affinity ... that allows the fast separation of His-tagged proteins ... resins but all of them show some affinity ...
... , ,,Application Guide, ,I. Description ,II. Product ... User ,IV. Protocol for Extraction of DNA from ... from Plant ,VI. Quantification of Amplified Products ... References , Contact Information , , ,Application Guide, , ...
Cached Biology Technology:High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 2High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 3High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 4High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 5High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 6High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 7High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 8High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 9High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 10High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system 11Double-Affinity Purification of GST-His Tagged Proteins Using Vivapure 8-to-96 Well Cobalt-Chelate Kit 2Double-Affinity Purification of GST-His Tagged Proteins Using Vivapure 8-to-96 Well Cobalt-Chelate Kit 3Double-Affinity Purification of GST-His Tagged Proteins Using Vivapure 8-to-96 Well Cobalt-Chelate Kit 4Protocol for GenomePlex Whole Genome Amplification from Plant 2Protocol for GenomePlex Whole Genome Amplification from Plant 3Protocol for GenomePlex Whole Genome Amplification from Plant 4Protocol for GenomePlex Whole Genome Amplification from Plant 5Protocol for GenomePlex Whole Genome Amplification from Plant 6
(Date:4/17/2014)... on a novel method to help kidney stone ... effective treatment possible., Kidney stones represent a major ... If left untreated, apart from being particularly painful, ... complications. In many patients treated successfully, stone recurrence ... pathological approach to diagnosis and treatment needs to ...
(Date:4/17/2014)... have detected new early-warning signs of the potential loss ... far-reaching implications for the diagnosis and treatment of diabetic ... Americans. , "We had not expected to see such ... said Ann Elsner, professor and associate dean in the ... study. "We set out to study the early signs, ...
(Date:4/17/2014)... immune system may fight cancers and viral infections. The ... treat illness. , The research, in mice, suggests that ... specialized squads of defenders that patrol only one ... the body. , Scientists at Washington University School of ... skin and uterus each has dedicated immune cells, which ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Some immune cells defend only 1 organ 2
... in Plant Science Automated conserved ... promoter evolution among grasses Within the genome of ... undergo little change in position and sequence over millions of ... these evolutionarily stable sequences, so-called conserved noncoding sequences (CNSs), are ...
... Investigators at Rollins School of Public Health at Emory ... Technology, have received a $4 million grant over four ... (Health and Exposome Research Center: Understanding Lifetime Exposures). The ... the United States. The HERCULES Center is ...
... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. The project is one of ...
Cached Biology News:Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... Microarrays designed for genome-wide microRNA expression profiling ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... microRNA Expression Profiling Service. Probe ... all known cow microRNAs (108 unique mature ...
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Viruses microRNA Microarray contains all known ...
...
... The Agilent 6850 Networked GC is an excellent ... footprint of a standard dual-channel GC, this one-channel ... GCs in the space of one. You get ... routine GC analyses in an instrument that has ...
Biology Products: